Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioArctic

330.80 SEK-0.12 %9.9, 17.29
Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.12 %
+5.22 %
+12.52 %
+10.71 %
+6.44 %
+16.81 %
+7.54 %
+123.21 %
+1,040.69 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Read more
Market cap
29.36B SEK
Turnover
28.15M SEK
Revenue
2B
EBIT %
62.97 %
P/E
28.64
Dividend yield-%
0.6 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...
8/28/2025, 10:21 AM
by Hawkmountdiver
7
About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.
8/28/2025, 2:16 PM
by j.sälli
2
Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB
8/28/2025, 10:28 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.11
2026

Interim report Q3'26

17.2
2027

Annual report '26

Regulatory press release03.09.2026, 06.00

BioArctic: Leqembi® subcutaneous formulation approved for initiation treatment in China

BioArctic
Press release01.09.2026, 07.00

BioArctic: Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

BioArctic
Regulatory press release31.08.2026, 17.30

Number of shares and votes in BioArctic AB (publ) as of August 31, 2026

BioArctic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
BioArctic, Audiocast, Q2'26
Webcast26.08.2026, 09.30

BioArctic, Audiocast, Q2'26

BioArctic
Regulatory press release26.08.2026, 08.00

Interim Report for the period April - June 2026

BioArctic
Press release24.08.2026, 14.05

BioArctic: Leqembi Iqlik® for initiation treatment launched in the US

BioArctic
Press release21.08.2026, 14.00

Modular Finance IR Consensus: Estimates compiled by Modular Finance on behalf of BioArctic

BioArctic
Press release19.08.2026, 11.15

BioArctic and Mesenkia enter oncology research collaboration

BioArctic
Press release19.08.2026, 08.30

Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST

BioArctic
Regulatory press release29.07.2026, 12.00

BioArctic: Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

BioArctic
Press release14.07.2026, 17.15

BioArctic: More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioArctic
Regulatory press release13.07.2026, 23.55

BioArctic: FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

BioArctic
Press release12.07.2026, 17.30

BioArctic: New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic
Press release30.06.2026, 08.00

BioArctic: New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

BioArctic
Regulatory press release22.06.2026, 07.32

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

BioArctic
Regulatory press release29.05.2026, 18.30

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

BioArctic
Regulatory press release28.05.2026, 18.30

Bulletin from the Annual General Meeting in BioArctic AB (publ)

BioArctic
Regulatory press release25.05.2026, 09.15

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BioArctic
BioArctic, Audiocast, Q1'26
Webcast20.05.2026, 09.30

BioArctic, Audiocast, Q1'26

BioArctic
Regulatory press release20.05.2026, 07.00

Interim Report for the period January - March 2026

BioArctic